Hematologic Malignancies and Plasma Cell Disorders
Research activity includes treatment strategies for relapsed or resistant B-cell acute lymphoblastic leukemia with measurable residual disease and light chain amyloidosis, with interest in immune-based and supportive approaches for marrow and organ involvement.
- Anti-CD19 CAR T-cell therapy
- Immunochemotherapy in amyloidosis
- Organ response in amyloid disease
The sponsor also supports studies in myelosuppression and hematologic recovery linked to complex cancer care.
Cardiovascular, Vascular, and Pulmonary Disorders
Clinical research spans acute heart failure, decompensated heart failure, myocarditis, inflammatory cardiomyopathy, and critical limb ischemia, as well as neonatal and adolescent circulatory conditions.
- SGLT-2 inhibitors in heart failure
- Immunosuppression in cardiac inflammation
- Persistent pulmonary hypertension of the newborn
Additional interest is shown in adolescent hypertension and limb perfusion therapies for advanced vascular disease.
Nephrology, Diabetes, and Metabolic Disease
Trials address primary IgA nephropathy, type 1 diabetes in children, and diabetic foot ulcer care, reflecting a strong focus on renal protection, glycemic preservation, and chronic complication management.
- Budesonide in IgA nephropathy
- Fenofibrate and pancreatic beta-cell function
- Stem cell-based wound care for diabetic foot disease
Research also includes therapies aimed at reducing proteinuria and preserving residual metabolic function in pediatric disease.
Pediatric Gastroenterology and Inflammatory Bowel Disease
The sponsor funds studies in Crohn’s disease affecting the upper gastrointestinal tract, with emphasis on pediatric inflammatory lesions in the esophagus, stomach, and duodenum.
- Topical budesonide for inflammatory lesions
- Children’s gastrointestinal inflammation
- Mucosal disease control
This area also connects with broader pediatric immune-mediated disease management.
Rare Diseases, Neurology, and Congenital Respiratory Disorders
Research extends to neurofibromatosis type 2, newborn respiratory failure linked to persistent pulmonary hypertension, and other uncommon pediatric conditions requiring specialized therapeutic options.
- Crizotinib in neurofibromatosis type 2
- Adolescent and neonatal rare disease care
- Respiratory and neurologic complications
These studies reflect interest in targeted treatment for genetically driven and early-life disorders.
